Quotes 5-day view Delayed Australian Stock Exchange
06/29/2022
06/30/2022
07/01/2022
07/04/2022
07/05/2022
Date
269.79(c)
269.06(c)
269.23(c)
274.8(c)
278.94(c)
Last
902 274
968 220
948 360
810 065
950 769
Volume
-1.55%
-0.27%
+0.06%
+2.07%
+1.51%
Change
Estimated financial data (e) (USD)
Sales 2022
10 730 M
-
-
Net income 2022
2 275 M
-
-
Net Debt 2022
7 484 M
-
-
P/E ratio 2022
38,8x
Yield 2022
1,10%
Sales 2023
13 548 M
-
-
Net income 2023
2 804 M
-
-
Net Debt 2023
10 984 M
-
-
P/E ratio 2023
32,4x
Yield 2023
1,29%
Capitalization
90 967 M
90 967 M
-
EV / Sales 2022
9,18x
EV / Sales 2023
7,53x
Nbr of Employees
25 000
Free-Float
95,0%
CSL Limited (CSL) is a biotechnology company engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. CSL provides a portfolio of life saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Its segments include CSL Behring and Seqirus. CSL Behring manufactures,...
All news about CSL LIMITED
News in other languages on CSL LIMITED
Analyst Recommendations on CSL LIMITED
KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CSL LIMITED
Short Term Mid-Term Long Term Trends Bullish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
15
Last Close Price
188,84 $
Average target price
216,68 $
Spread / Average Target
14,7%
Please enable JavaScript in your browser's settings to use dynamic charts.